Exclusive Summary

• Covers dual indications for depression and chronic neuropathic pain, targeting a massive global market of over 300 million patients with robust rigid demand.
• Recognized as a first-line classic SNRI drug recommended by multiple global guidelines, featuring a full range of dosages (20/30/60mg) to perfectly meet clinical titration and maintenance needs.
• With originator patents fully expired, it leverages China's highly competitive supply chain cost advantages to provide overseas distributors with substantial profit margins for local bidding.
• The enteric-coated formulation presents specific technical barriers; the supplier ensures stable delivery and provides standard CTD dossiers to support rapid regulatory registration overseas.